Fresenius Kabi Launches Posaconazole Injection for Fungal Infections

Fresenius Kabi is posaconazole, an alternative to Noxafil, which treats or prevents severe fungal infections in adults and children at risk of developing fungal infections due to a weakened immune system. Posaconazole injection, currently available in the United States, is the latest addition to Fresenius Kabi's portfolio of more than 30 anti-inflammatory molecules.

Posaconazole injection, available at 300 mg per 16.7 mL vial, is used to treat invasive aspergillosis, a severe fungal infection in adults and adolescents 13 years and older. It is also used to prevent Aspergillus and Candida infections in critically ill patients, including adults and pediatric patients over two years of age. "The introduction of injectable posaconazole demonstrates Fresenius Kabi's continued commitment to expanding our portfolio of cost-effective options for treating and preventing life-threatening diseases," said John Ducker, President and CEO of Fresenius Kabi USA.

Posaconazole Injection is manufactured at the company's pharmaceutical manufacturing facility in Grand Island, New York. Fresenius Kabi has invested nearly $1 billion in expanding and modernizing its US pharmaceutical production and distribution network. More than 70% of the product lines sold by Fresenius Kabi in the United States are drugs on the FDA's

Essential Drug List. Lindsey Thomas, Chief Marketing Officer of Fresenius Kabi USA, said, "Our investment will help patients get the care they need, when and where they need it most."